Prostate cancer is a very common disease in industrialized countries and it is known to be androgen-dependent. The human SRD5A2 gene encodes the prostatic (or type II) steroid 5a-reductase, which catalyses the irreversible conversion of testosterone to dihydrotestosterone (DHT), the most active androgen in the prostate. We have sequenced the entire protein-coding region of this locus in 30 microdissected prostate adenocarcinomas. We identified a total of 17 de novo amino-acid substitutions in 13 of these tumors. We also identified six additional silent substitutions. In total, 18 out of 30 (60%) of the tumors examined had de novo somatic substitutions in the prostatic steroid 5a-reductase-coding region. We also characterized all of the SRD5A2 missense substitutions biochemically and pharmacologically, using three 5a-reductase inhibitors, including finasteride. The biochemical parameters of the distinct 5a-reductase missense substitutions varied substantially. We note that two out of the three recurrent SRD5A2 missense substitutions increased 5a-reductase in vitro activity, while the third one is essentially neutral. These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients. Our pharmacologic studies also reveal substantial variability for each 5a-reductase inhibitor. These data, therefore, should be taken into account in both prevention as well as therapeutic trials of prostate cancer utilizing 5a-reductase inhibitors.
Introduction
Prostate cancer is a very common disease in the industrialized world: 220 900 men will be newly diagnosed and 28 900 men are predicted to die of the disease in the US this year alone (Jemal et al., 2003) . Prostate cancer is dependent on androgens for growth, and we have previously proposed that variations in androgen metabolism may affect a man's risk of this disease (Ross et al., 1998) . We have reported evidence that increased intraprostatic androgen metabolism, particularly through the enzyme steroid 5a-reductase, may play an important role in predisposition to prostate cancer (Ross et al., 1998; Makridakis et al., 1999) . Steroid 5a-reductase catalyses the conversion of testosterone to dihydrotestosterone (DHT), the most potent androgen in the prostate (e.g. Cheng et al., 1993) . Thus, genetic variants encoded by the SRD5A2 gene and other androgen-metabolic enzymes may play an important role in predisposition to prostate cancer (Ross et al., 1998) . We have also reported data on somatic events at the SRD5A2 locus . Thus, this gene may play a role both in predisposition and in progression of prostate cancer.
Finasteride is a specific competitive inhibitor of the SRD5A2 gene product (Stoner, 1996) . The recent report of the prostate cancer prevention trial (PCPT) showed that treatment of men 55 years of age or older with finasteride resulted in a significant decrease in the rate of prostate cancer measured over a 7-year period (Thompson et al., 2003) , suggesting that finasteride prevents or delays the appearance of prostate cancer. However, finasteride treatment also resulted in a significant increase in the incidence of prostate tumors of high-grade Gleason (specifically grade 7 or higher; Thompson et al., 2003) .
We report the identification of 10 de novo SRD5A2 missense substitutions in somatic prostate cancer tissue. Four of these amino-acid substitutions produce significantly more DHT in in vitro enzyme assays. Some of these missense mutations were also recurrent. This observation suggests that these SRD5A2 somatic mutations may play an important role in prostate cancer progression and may explain the unexpected finding of an increase in high-grade prostate cancer in the PCPT (described by Thompson et al., 2003) .
Results
We examined the entire protein-coding region of the SRD5A2 gene for somatic (or de novo) mutations by microdissection of prostate cancer tissue followed by automated DNA sequencing of the isolated tumor DNA. We have identified a total of 18 amino acid (or missense) substitutions in 13 of 30 tumors (Figure 1) . Three of these missense substitutions were recurrent (Table 1) , including the most common one, A49T (alanine-49 to threonine), which has also been found to be involved in prostate cancer predisposition (Makridakis et al., 1999) . We found an additional six polymorphic substitutions in seven tumors (Figure 1 and data not shown). One of these polymorphisms, C2247T (cytoscine-2247 to thymine), is also recurrent (it was found in two tumors, Table 1 ). A total of 18 tumors had acquired additional somatic changes at the SRD5A2 locus (Table 2 and data not shown) . Thus, about 60% of the tumors examined show evidence of de novo somatic substitutions in the SRD5A2 coding region.
Parallel examination of the corresponding peripheral blood lymphocyte (i.e. constitutional or 'germline') DNA was also performed. These analyses failed to detect any of these novel substitutions found in tumor tissue, except for tumor sample 7 (Table 2) . Constitutional DNA of that sample was already heterozygous for the A49T missense mutation (Table 2 ). This mutation, however, was essentially homozygote in the tumor tissue since the intensity of the mutant exceeded 89% (Table 2) . Therefore, an additional somatic event must have occurred in this tumor at this particular site. Interestingly, Silent substitutions C2247T 2 7
The total number of prostate tumor tissues analysed is 30. Missense substitutions are indicated by the normal amino acid and the codon number followed by the mutant amino acid, using the one letter code. DNA substitutions are indicated by the normal base and the base number followed by the mutant base. Frequencies are approximate DNA substitutions are indicated by the normal base and the base number (taken from Genbank Accession number L03843) followed by the mutant base. Amino acids similarly use the one letter code and codon number. Intensities were determined once for SSCP runs and at least three times on different sequencing runs. These data are reported as the mutant peak intensity in % of total peak intensity. Previously identified mutations (LOH being loss of heterozygosity and GI being genomic (i.e. microsatellite) instability) are from . Sample 7 was heterozygous for the A49T mutation in its constitutional DNA and is marked by an asterisk. The constitutional DNA data are, therefore, shown in parenthesis Somatic SRD5A2 mutations in prostate cancer N Makridakis et al we detected two additional somatic events in this tumor sample, an amino-acid substitution (A248V) and a polymorphism (C2247T) ( Figure 1 , Table 2 and data not shown).
Analysis of the distribution of the somatic SRD5A2 missense substitutions by tumor tissue reveals that four tumors have prevalent (more than 50% mutant) missense substitutions in the SRD5A2 gene (Table 2 ). In three out of the four cases, the prevalent missense substitution is the A49T ( Table 2 ). The A49T is also the most prevalent missense substitution among tumors that have another missense substitution in the SRD5A2 gene, in addition to the A49T (Table 2) . Table 2 also reveals that the majority of the tumor samples that have missense substitutions also display previously identified somatic events at the SRD5A2 locus (five of those samples had microsatellite instability and two loss of heterozygosity). Thus, the SRD5A2 gene is a common target for multiple somatic events in prostate cancer tissue.
We then analysed the biochemical characteristics of each of the variant 5a-reductase proteins after transient expression of the respective reconstructed clones in mammalian cells followed by in vitro enzyme assays (Table 3) . Three classes of missense substitutions are evident (Table 3) : (i) those that result in increased activity compared to wild-type protein, evidenced by the increased apparent V max (V3I, A49T, F118L, and A248V), (ii) those that display roughly normal (or 'wild type') activity (V63M, G183D, and L226P), and (iii) those that result in decreased activity compared to the wild-type protein (V189A, G191E, and L221P). For each missense substitution, changes in the apparent V max are accompanied by changes in the apparent K m for either testosterone or NADPH, or both (Table 3) . Interestingly, most of the missense substitutions appear to increase the K m for testosterone, including all of those that increase the apparent V max (Table 3) . Three of the missense substitutions identified (A49T, L226P, and A248V) result in increased V max /K m ratios (Table 3) , and thus are expected to produce more efficient enzymes (Nelson and Cox, 2000) . All of the missense substitutions display optimum activity at the optimum pH for the wild-type protein (pH 6), with the exception of the L221P (leucine-221 to proline) substitution, which has an increased optimal pH of 6.5 (Table 3) .
Characterization of the apparent inhibitory constant (K i ) for three competitive 5a-reductase inhibitors (finasteride, dutasteride, and PNU-157706; Makridakis et al., 2000) indicates that there is significant pharmacogenetic variation compared to the wild-type protein for most of the somatic SRD5A2 missense substitutions (Table 4) . The apparent K i for the selective 5a-reductase type II inhibitor finasteride (Stoner, 1996) varied 36-fold, from 5-180 nM (Table 4 ). The variation of the apparent K i for PNU-157706 (di Salle et al., 1998) was about 16-fold, ranging from 1.1 to 18 nM (Table 4 ). The most significant variation of the apparent K i though was for dutasteride (Frye et al., 1998) , which varied 85-fold, spanning the range from 1.1 to 93 nM (Table 4) .
Discussion
We report here common de novo somatic mutations in the SRD5A2 (prostatic or type II steroid 5a-reductase) Missense substitutions are indicated by the normal amino acid and the codon number followed by the mutant amino acid, using the one letter code. The experimental range for the normal (wt) type II 5a-reductase enzyme is given in parentheses Table 4 Pharmacogenetic analysis of somatic SRD5A2 missense substitutions . In addition, the majority of the SRD5A2 missense substitutions were present in samples that were previously shown to have either microsatellite instability or LOH at the SRD5A2 locus (Table 2) . Therefore, the SRD5A2 gene is a common target for multiple somatic events in prostate cancer tissue. Three of the SRD5A2 missense substitutions and one of the polymorphisms were recurrent (Table 1) . Moreover, preliminary data suggest that the two most common missense substitutions, A49T and V63M (Table 1) , are also present in an independent data set of prostate tumor tissues (the A49T mutation was recurrent again; data not shown). It is of special interest that the most common somatic event found, the A49T mutation, was more prevalent than the normal allele (more than 50% mutant) in most of the tumors that contained it (three out of five tumors; Table 2 ). This mutation has been previously shown to be associated with prostate cancer predisposition, and it is known to increase 5a-reductase activity in vitro (Makridakis et al., 1999) . Thus, the A49T mutation in the SRD5A2 gene may contribute to the development as well as the progression of prostate cancer, through increased DHT production.
Some of the prostate tissues examined had more than one somatic SNPs and one sample (sample 7) had three (the A49T, A248V, and C2247T SNPs; Figure 1 , Table 2 , and data not shown). The latter two SNPs were present at much lower levels than the A49T mutation in this tumor sample (Table 2 ). These data suggest either multiple somatic mutation events in this sample or a large-scale rearrangement. We favor the former hypothesis since we detected microsatellite instability previously in this tumor (Table 2 ) but no LOH.
Biochemical analysis of the SRD5A2 missense substitutions, we identified, in vitro suggests that four of these substitutions significantly increase steroid 5a-reductase activity (by increasing the apparent V max ), three are neutral, and three decrease steroid 5a-reductase activity (Figure 2 and Table 3 ). With regards to enzyme efficiency, three missense substitutions result in significantly higher V max /K m ratios while the rest do not (Table 3) . Moreover, two out of the three recurrent SRD5A2 somatic missense substitutions, A49T and A248V, significantly increase steroid 5a-reductase activity, while the third, V63M, is essentially neutral (Figure 2 and Tables 1 and 3 ). Thus, none of the recurrent SRD5A2 somatic missense substitutions result in decreased steroid 5a-reductase activity (Figure 2 and Tables 1 and 3 ). Both the A49T and the A248V somatic mutations display significantly higher V max /K m ratios, a measure of catalytic efficiency (Nelson and Cox, 2000) than the normal enzyme (Table 3) . Therefore, most recurrent SRD5A2 somatic missense substitutions result in increased catalytic efficiency. In addition, the most common missense substitution (A49T ; Table 1 ) is also the mutation that results in the highest steroid 5a-reductase activity in vitro (Figure 2 and Table 3 ) and is the most prevalent mutation in each of the tissues that it is present (Table 2) . Taking into account the recurrent mutations, about 20% of the prostate tumor samples have somatic SRD5A2 mutations that significantly activate steroid 5a-reductase, while only 7% have SRD5A2 mutations that reduce enzyme activity significantly. These observations are consistent with the hypothesis that increased DHT levels are important for prostate tumor progression. The small number of tumors that have inactivating steroid 5a-reductase mutations may contain additional mutations in other androgen metabolic genes so that the overall result is stimulation of the androgen receptor signaling pathway, despite lower steroid 5a-reductase activity. Future studies on other androgen metabolic genes will address this hypothesis.
The majority of the somatic SRD5A2 missense substitutions that affected the apparent K m for testosterone (Table 3 ) also affected the apparent K i for all three 5a-reductase inhibitors, finasteride, dutasteride, and PNU157706 (Table 4 ). This finding is consistent with the fact that all of these drugs are competitive inhibitors of 5a-reductase (Stoner, 1996; di Salle et al., 1998; Frye et al., 1998) . All of the somatic SRD5A2 missense substitutions analysed significantly modified the apparent K i of the normal protein for all three steroid 5a-reductase inhibitors examined (Table 4) . PNU157706 was the steroid 5a-reductase inhibitor that exhibited the lowest apparent K i for most of the (Table 4) . The distribution of the apparent K i for the distinct SRD5A2 missense substitutions varied substantially, from 16-fold (for PNU157706) to 84-fold (for dutasteride) (Table 4) . This finding is also true if one focuses only on the recurrent somatic SRD5A2 mutations (Tables 1 and 4) , or on the naturally occurring SRD5A2 missense substitutions reported previously (Makridakis et al., 2000) . This significant pharmacogenetic variation at the SRD5A2 locus should be taken into account when using competitive steroid 5a-reductase inhibitors for the treatment or prevention of prostate cancer. For example, the Prostate Cancer Prevention Trial (PCPT) recently reported that finasteride treatment in men followed over 7 years resulted in a significant decrease in the overall incidence of prostate cancer, and also in a significant increase in the incidence of high-grade prostate tumors (Thompson et al., 2003) . Given the pharmacogenetic variability for finasteride presented here and elsewhere (Makridakis et al., 2000) for both constitutional DNA SNPs and somatic SRD5A2 mutations, future trials such as the PCPT should consider genotyping men (especially men that took finasteride and developed high-grade prostate tumors) for SRD5A2 mutations. This conclusion is also strengthened by the fact that two out of the three recurrent somatic missense substitutions increased the K i for finasteride (Table 4) . Thus, constitutional and somatic genotypes may be critical for finasteride efficacy. The somatic missense substitutions are distributed throughout the protein-coding region of the human SRD5A2 gene (Figure 1) . However, there appears to be a clustering of missense substitutions particularly in the carboxy-terminal third of the protein, specifically codons 183-248 (Figure 1 ). This part of the steroid 5a-reductase enzyme has been proposed to be involved in substrate and cofactor binding (Wigley et al., 1994; Makridakis et al., 2000) . We also note the relative rarity of substitutions of any kind in the central portion of the SRD5A2 protein, another observation previously made by us but not others (Wigley et al., 1994; Makridakis et al., 2000) . We suspect that this difference may be due to the different phenotypes investigated by Russell and co-workers, male pseudohermaphroditism (cf. Wigley et al., 1994 ) a rare autosomal recessive disorder which results in mutations that severely impair enzymatic activity, and us who are interested in mutations and polymorphisms in prostate cancer that presumably activate steroid 5a-reductase (e.g. Makridakis et al., 1999 Makridakis et al., , 2000 . Thus, male pseudohermaphrodistism mutations are loss of function mutations (Wigley et al., 1994) while activating mutations in prostate cancer should be gain of function mutations (Makridakis et al., 1999) . Analysis of the apparent binding constants for the distinct missense substitutions (Table 3) can provide information about the number of domains that comprise the binding pocket of the prostatic steroid 5a-reductase, a protein that has never been purified. Only missense substitutions confined in the carboxy-terminal third of the protein affect the apparent K m for the NADPH cofactor (Table 3 and Figure 3 ). The binding site for the substrate (testosterone) though appears to be bipartite, both amino-terminal and carboxy-terminal domains are important for binding (Table 3 and Figure 3 ). These findings confirm earlier observations based on SRD5A2 missense substitutions found on constitutional DNA (Makridakis et al., 2000) . However, data reported here significantly expands the extent of the testosterone-binding site for this enzyme, at least based on its primary (linear) structure (Figure 3) .
Common karyotypic abnormalities have been reported on the short arm of chromosome 2 in prostate cancer tissue and cell lines (Brothman et al., 1990) . Interestingly, the chromosomal location of the SRD5A2 gene is in chromosome band 2p23 (Thigpen et al., 1992) . Therefore, it is possible that the chromosomal abnormalities identified previously (e.g. Brothman et al., 1990) relate in part with the somatic mutations we identified in the SRD5A2 locus and this report). We note that another study that utilized single-nucleotide polymorphic (SNP) arrays for the analysis of LOH from laser capture microdissected prostate cancer samples did not present any data on chromosome 2 (Lieberfarb et al., 2003) .
Somatic mutations in prostate cancer have been of intense interest to researchers (e.g. Brothman et al., 1990; Gottlieb et al., 1999) . Previous investigations, however, have never focused specifically on androgenmetabolic genes. In fact, there are only two publications addressing such genes to our knowledge (Macoska et al., 1992; . These reports investigated the type I steroid 5a-reductase gene (SRD5A1) by Southern blotting alone (Macoska et al., 1992) and the type II steroid 5a-reductase (SRD5A2) gene by polymerase chain reaction (PCR) analysis of a single-dinucleotide repeat . Thus, this report is the first to systematically investigate the entire coding sequence of an androgen-metabolic gene for somatic mutations in prostate cancer. We propose that these genes are likely to be important targets in tumor progression since the disease is androgen-dependent at least early in its (Wigley et al., 1994; Makridakis et al., 2000) . The positions of amino acids 100 and 200 are indicated as reference points Somatic SRD5A2 mutations in prostate cancer N Makridakis et al development (Cheng et al., 1993) . Furthermore, the androgen receptor (AR) gene is also mutated in some prostate cancer tissues (e.g. Visakorpi et al., 1995; Gottlieb et al., 1999) . Thus, the SRD5A2 gene as well as other androgen-metabolic loci together with the AR may play an important role in tumor progression. Systematic analyses of such genes may identify valuable prognostic markers and offer the opportunity for rational intervention.
Most of the studies that compared the SRD5A2 mRNA levels between normal human prostate and prostate cancer have reported decreased SRD5A2 gene expression (Luo et al., 2003) . To reconcile these findings with the documented androgen dependence of prostate cancer in all disease stages but the metastatic and the success of finasteride in the PCPT cancer prevention trial, we propose that somatic SRD5A2 gene mutations that activate 5a-reductase may be common in prostate cancer tissue.
The large number of de novo mutations identified enables us to analyse the molecular nature of the somatic events occurring in those prostate tumors. The vast majority of those somatic events are transitions that occur at a nine-nucleotide purine-rich motif (manuscript in preparation). These observations suggest that the somatic SRD5A2 mutations may be generated through a distinct molecular mechanism. It may also be of technical interest to note that in general both the sequencing and single-strand conformation polymorphism (SSCP) methods gave similar quantitation of all somatic mutations (Table 2 ). This finding suggests that both methods can accurately detect and quantitate such mutations. Preliminary analyses of the distribution of the SRD5A2 mutations by stage indicates that the majority of the SRD5A2 somatic events occurred rather early during prostate cancer progression compared to the overall stage distribution of the samples (Table 2 and .
In summary, we report here both missense and silent somatic (de novo) substitutions in the proteincoding region of the SRD5A2 gene (encoding the prostatic steroid 5a-reductase) in about 60% of prostate tumors examined. Some of these substitutions were recurrent. Kinetic analysis of the missense SRD5A2 substitutions revealed significant pharmacogenetic and biochemical variation. The majority of the recurrent missense SRD5A2 substitutions resulted in significantly increased apparent V max in vitro. These common SRD5A2 somatic mutations may be relevant to prostate tumor progression and their biochemical and pharmacogenetic consequences may help in individualized cancer treatment (and perhaps even prevention).
Materials and methods

DNA samples from tissue
Samples and stage information are as in . Briefly, tumor prostate and peripheral blood samples were obtained from 30 patients who underwent radical prostatectomy between 1988 and 1995 at the USC/Norris Comprehensive Cancer Center. These patients were heterozygous for the (TA) n marker in the SRD5A2 gene . Tumor staging was carried out according to the TNM classification system (Schroder et al., 1992) .
Mutation identification
DNA was extracted from microdissected tissue exactly as described above (see also . Primers for PCR amplification of SRD5A2 exons 1-5 were described previously (Makridakis et al., 1997 ). An additional primer was used to amplify the upstream part of exon 1 using the forward primer 5 0 -GAAGCCCTCCGGC-TACGGG-3 0 and the reverse primer 5 0 -TGCACTGGGCGCC CGCAAG-3 0 . PCR products were obtained by thermal cycling using a RoboCycler Gradient 40 system (Stratagene; La Jolla, CA, USA) under the following conditions: an initial denaturation step at 941C was performed for 2 min followed by 43 cycles of denaturation at 951C for 1 min, annealing at 601C for 1 min, and 2 min extension at 721C. All PCR products were then extended at 721C for 5 min. PCR products were analysed by SSCP as described previously (Makridakis et al., 1997) . Sequencing analysis was carried out using the ABI PRISMt Dye Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer; Foster City, CA, USA). Sequencing reactions were run, analysed and quantitated on an ABI PRISM 377 DNA Sequencer (Foster City, CA, USA) using the software provided by ABI. Signal intensities of SSCP bands were measured by the ImageQuant software (Sunnyvale, CA, USA).
Similar analyses of the matched constitutional ('germ line') DNA were performed to verify that the somatic mutations in fact occurred de novo.
Mutation characterization
Individual mutations were reconstructed in the SRD5A2 cDNA mammalian expression vector pS303-5aR2 (originally obtained from Dr D Russell, Southwestern Medical College, Dallas, TX, USA; see Makridakis et al., 2000) , by sitedirected mutagenesis using the QuickChange kit (Stratagene, San Diego, CA, USA) with custom primers (Invitrogen, Carlsbad, CA, USA). The distinct SRD5A2 cDNAs were electroporated in cos7 cells together with a b-galactosidase control plasmid, and the respective protein extracts were collected 48 h later, by sonication. b-Galactosidase assay was then performed to normalize the extracts for differences in transfection efficiency. Normalized extract amounts were then used for 5a-reductase activity assay, as described (Makridakis et al., 2000) . Briefly, a mixture containing 5 mM NADPH, 0.2 mM -testosterone, various amounts of unlabeled testosterone, and 0.1 M Tris-citrate buffer (pH 6) was added to the normalized protein extracts on ice. The reactions were placed at 371C for 10 min. Subsequently, the reactions were stopped with methylene chloride, and after extraction of the organic phase, steroids were dried, redissolved and separated by thinlayer chromatography (TLC) (Makridakis et al., 1999 (Makridakis et al., , 2000 . Dried TLC plates were then exposed on phosphorimager screens (Molecular Dynamics; Mountain View, CA, USA) and quantified on a Storm phosphorimager (Molecular Dynamics; Mountain View, CA, USA). Then, substrate to product conversion values were translated into velocity values, and plotted using Cricket Graph 1.3 (Cricket software; Malvern, PA, USA). Lineweaver-Burk plots were used to calculate V max and K m values. K i values were calculated by similar plots after the inclusion of different amounts of inhibitors together with 1.6 mM testosterone, in 5a-reductase assays. Experimental details can be found in Makridakis et al., 2000. Abbreviations DHT, dihydrotestosterone; LOH, loss of heterozygosity; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; SRD5A2, steroid 5a-reductase type II locus; SSCP, singlestrand conformation polymorphism.
